BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, April 12, 2026
See today's BioWorld Asia
Home
» More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal
To read the full story,
subscribe
or
sign in
.
More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal
Feb. 4, 2025
By
Marian (YoonJee) Chu
A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
BioWorld Asia
Deals and M&A
Cancer
Gastrointestinal
Antibody-drug conjugate
Asia-Pacific
China
U.S.
